-
Phase 3 Trial of Stereotactic Body Radiotherapy in Localized Prostate Cancer
Read articleN. van As, C. Griffin, A. Tree, J. Patel, P. Ostler, H. van der Voet, A. Loblaw, W. Chu, D. Ford, S. Tolan, S. Jain, P. Camilleri, K. Kancherla, J. Frew, A. Chan, O. Naismith, J. Armstrong, J. Staffurth, A. Martin, I. Dayes, P. Wells, D. Price, E. Williamson, J. Pugh, G. Manning, S. Brown, S. Burnett, and E. Hall
Published in The New England Journal of Medicine, 2024
-
Clinical implementation of real time motion management for prostate SBRT: A radiation therapist’s perspective
Read articleJoanne Mitchell Angus Killean, Duncan B. McLaren , Michael Trainer, Donna Burns Pollock , Susan Adamson, Joella Wright , Laura McKernan, William H. Nailon.
Published in Science Direct, 2024
-
State of the art and future challenges of urethra‑sparing stereotactic body radiotherapy for prostate cancer: a systematic review of literature
Read articleJennifer Le Guevelou, Davide Giovanni Bosetti, Francesco Castronovo, Antonio Angrisani, Renaud de Crevoisier & Thomas Zilli
Published in World Journal of Urology, 2023, Sept 5th
-
Noninvasive inter- and intrafractional motion control in ultrahypofractionated radiation therapy of prostate cancer using RayPilot HypoCath™-a substitute for gold fiducial-based IGRT?
Read articleJohannes Berchtold , Carmen Winkler , Josef Karner , Michael Groher , Christoph Gaisberger, Felix Sedlmayer and Frank Wolf
Published in Strahlenther Onkol, 2023 Aug 25. (Online ahead of print)
-
Dosimetric Impact of Intrafraction Prostate Motion and Interfraction Anatomical Changes in Dose-Escalated Linac-Based SBRT
Read articleValeria Faccenda, Denis Panizza, Martina Camilla Daniotti, Roberto Pellegrini, Sara Trivellato, Paolo Caricato, Raffaella Lucchini, Elena De Ponti and Stefano Arcangeli
Published in Cancers 2023, 15(4), 1153
-
Intensity-modulated radiotherapy versus stereotactic body radiotherapy for prostate cancer (PACE-B): 2-year toxicity results from an open-label, randomised, phase 3, non-inferiority trial
·
Read articleAlison C Tree, Peter Ostler, Hans van der Voet, William Chu, Andrew Loblaw, Daniel Ford, Shaun Tolan, Suneil Jain, Alexander Martin, John Staffurth, John Armstrong, Philip Camilleri, Kiran Kancherla, John Frew, Andrew Chan, Ian S Dayes, Aileen Duffton, Douglas H Brand, Daniel Henderson, Kirsty Morrison, Stephanie Brown, Julia Pugh, Stephanie Burnett, Muneeb Mahmud, Victoria Hinder, Olivia Naismith, Emma Hall*, Nicholas van As*, on behalf of the PACE Trial Investigators.
-
Intrafraction Prostate Motion Management During Dose-Escalated Linac-Based Stereotactic Body Radiation Therapy
Read articleDenis Panizza 1,2*, Valeria Faccenda 1,3, Raffaella Lucchini 2,4, Martina Camilla Daniotti 1,3, Sara Trivellato1 , Paolo Caricato 1,3, Valerio Pisoni 4, Elena De Ponti 1,2 and Stefano Arcangeli 2,4
1 Medical Physics Department, ASST Monza, Monza, Italy, 2 School of Medicine and Surgery, University of Milan Bicocca, Milan, Italy, 3 Department of Physics, University of Milan, Milan, Italy, 4 Radiation Oncology Department, ASST Monza, Monza, Italy
-
Ultra-hypofractionated versus conventionally fractionated radiotherapy for prostate cancer (HYPO-RT-PC): patient-reported quality-of-life outcomes of a randomised, controlled, non-inferiority, phase 3 trial
Read articlePer Fransson, PhD, Per Nilsson, PhD, Adalsteinn Gunnlaugsson, MD, Lars Beckman, MD, Björn Tavelin, BSc, David Norman, BSc, Camilla Thellenberg-Karlsson, MD, Prof Morten Hoyer, MD, Magnus Lagerlund, MD, Jon Kindblom, MD, Claes Ginman, MD, Bengt Johansson, MD, Kirsten Björnlinger, MD, Mihajl Seke, MD, Måns Agrup, MD, Prof Björn Zackrisson, MD, Elisabeth Kjellén, MD, Prof Lars Franzén, MD, Prof Anders Widmark, MD
